Hetero USA

Hetero USA Inc. is the U.S. subsidiary of the privately held Indian pharmaceutical group known as Hetero (flagship entity Hetero Labs Limited, incorporated 1989 and formerly Pharmasia Laboratories; the group brand dates to 1993). Hetero USA is a Delaware corporation with a principal U.S. place of business at 1035 Centennial Avenue, Piscataway, New Jersey. Per its own corporate disclosure filings, it is 50/50 owned by Hetero Labs Ltd. and Hetero Drugs Ltd.; no publicly traded company holds 10% or more. It is a closely held, non-listed group. The wider Hetero Group reports roughly 20,000–30,000 employees and operates ~36 manufacturing sites; Hetero Labs Limited alone disclosed ~₹16,500 crore revenue for FY2025 (secondary sources, The Company Check / CARE Ratings). It is not public and has no ticker.

Operations. Hetero is a generic and contract pharmaceutical manufacturer. Core lines are active pharmaceutical ingredients (APIs) — it is frequently described as the world's largest producer of anti-retroviral APIs — and finished dosage formulations (generics) across cardiovascular, oncology, HIV, and other therapies. Hetero USA functions mainly as the group's U.S. commercial and regulatory arm: it acts as U.S. regulatory agent for Hetero Labs units and distributes/sells Hetero generic products in the U.S. market.

Litigation posture. Hetero USA appears in the tracked data solely as a defendant (0 plaintiff cases, 1 defendant case), which is the profile of an operating company defending products-liability-style ANDA suits rather than a patent assertion entity. Its cases are brought by branded pharmaceutical manufacturers enforcing patents against generic filers; the venue here is the District of New Jersey (D.N.J.), which is habitual for Hatch-Waxman pharmaceutical litigation, not a plaintiff-friendly patent-assertion district.

Notable case. The single tracked matter is Celgene Corporation v. Hetero Labs Ltd. et al., D.N.J., a Hatch-Waxman/Paragraph IV dispute in which Hetero entities are defendants responding to a branded manufacturer's infringement claims tied to an Abbreviated New Drug Application. Related public records also show Hetero entities in other ANDA disputes (e.g., Ingenus Pharmaceuticals v. Hetero USA) and multi-district valsartan products-liability litigation. No patent-assertion funding or NPE characteristics are indicated.